RE: a) - how does following up a patient six months later demonstrate superiority over SOC? Isn't superiority measured around the time of the cu64 procedure? To demonstrate superiority over SOC six months later, wouldn't the patient need another SOC scan (and I don't believe this is part of the trial protocol).
2) - the Safety Review Committee recommends higher doses / multiple doses of cu67 just weeks after patient dosing. Is "longish safety monitoring" really part of cu64 trials?
Still struggling to understand why it takes such an extended time post final patient dosing to make an FDA submission for these diagnostic trials - but now its only from an interest perspective (too late for capital protection). Either way, it just firms up the expectation that first revenue is at least as far away as 2028.
CU6 Price at posting:
$1.45 Sentiment: Sell Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)